Roles of STAT3 in leukemia (Review)

  • Authors:
    • Yin Shi
    • Zhen Zhang
    • Xintao Qu
    • Xiaoxiao Zhu
    • Lin Zhao
    • Ran Wei
    • Qiang Guo
    • Linlin Sun
    • Xunqiang Yin
    • Yunhong Zhang
    • Xia Li
  • View Affiliations

  • Published online on: April 30, 2018     https://doi.org/10.3892/ijo.2018.4386
  • Pages: 7-20
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Leukemia is a type of hematopoietic malignancy, and the incidence rate in the United States and European Union increases by an average of 0.6 to 0.7% annually. The incidence rate in China is approximately 5.17/100,000 individuals, and the mortality rate is 3.94/100,000 individuals. Leukemia is the most common tumor affecting children and adults under 35 years of age, and is one of the major diseases leading to the death of adolescents. Signal transducer and activator of transcription 3 (STAT3) is a vital regulatory factor of signal transduction and transcriptional activation, and once activated, the phosphorylated form of STAT3 (p-STAT3) is transferred into the nucleus to regulate the transcription of target genes, and plays important roles in cell proliferation, differentiation, apoptosis and other physiological processes. An increasing number of studies have confirmed that the abnormal activation of STAT3 is involved in the development of tumors. In this review, the roles of STAT3 in the pathogenesis, diagnosis, treatment and prognosis of leukemia are discussed in the aspects of cell proliferation, differentiation and apoptosis, with the aim to further clarify the roles of STAT3 in leukemia, and shed light into possible novel targets and strategies for clinical diagnosis and treatment.

References

1 

Chen WQ, Shan BE, Zheng SR, Lin GZ, Chen JZ, Chen JG and He YT: Analysis of incidence and mortality of leukemia in registration areas of China from 2003 to 2007. Tumor. 32:251–255. 2012.In Chinese.

2 

Amitay EL and Keinan-Boker L: Breastfeeding and childhood leukemia incidence: Ameta-analysis and systematic review. JAMA Pediatr. 169:e1510252015. View Article : Google Scholar

3 

Redaelli A, Stephens JM, Laskin BL, Pashos CL and Botteman MF: The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Rev Anticancer Ther. 3:311–329. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Namanja AT, Wang J, Buettner R, Colson L and Chen Y: Allosteric communication across STAT3 domains associated with STAT3 function and disease-causing mutation. J Mol Biol. 428:579–589. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar

6 

Yu H and Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI

7 

Villarino AV, Kanno Y, Ferdinand JR and O'Shea JJ: Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 194:21–27. 2015. View Article : Google Scholar :

8 

Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ: Stat3 signaling in acute myeloid leukemia: Ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 117:5701–5709. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H and Wetzler M: Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 99:252–257. 2002. View Article : Google Scholar : PubMed/NCBI

10 

Rezvani K and Barrett J: STAT3: The 'Achilles' heel for AML? Blood. 123:1–2. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Redell MS: A STAT3 decoy lures AML out of hiding. Blood. 127:1628–1629. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Yue P and Turkson J: Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs. 18:45–56. 2009. View Article : Google Scholar :

13 

Zhang T, Kee WH, Seow KT, Fung W and Cao X: The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol Cell Biol. 20:7132–7139. 2000. View Article : Google Scholar : PubMed/NCBI

14 

Seidel HM, Milocco LH, Lamb P, Darnell JE Jr, Stein RB and Rosen J: Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc Natl Acad Sci USA. 92:3041–3045. 1995. View Article : Google Scholar : PubMed/NCBI

15 

Song L and Shen BF: New development on Jak/STAT sigal transduction pathway. Immunol J. 16:68–71. 2000.In Chinese.

16 

Dewilde S, Vercelli A, Chiarle R and Poli V: Of alphas and betas: Distinct and overlapping functions of STAT3 isoforms. Front Biosci. 13:6501–6514. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Kim BH, Yi EH and Ye SK: Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch Pharm Res. 39:1085–1099. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Ren Z, Mao X, Mertens C, Krishnaraj R, Qin J, Mandal PK, Romanowski MJ, McMurray JS and Chen X: Crystal structure of unphosphorylated STAT3 core fragment. Biochem Biophys Res Commun. 374:1–5. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Chakraborty A and Tweardy DJ: Stat3 and G-CSF-induced myeloid differentiation. Leuk Lymphoma. 30:433–442. 1998. View Article : Google Scholar : PubMed/NCBI

20 

Ilaria RL Jr: STAT isoforms: Mediators of STAT specificity or leukemogenesis? Leuk Res. 25:483–484. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Becker S, Groner B and Müller CW: Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature. 394:145–151. 1998. View Article : Google Scholar : PubMed/NCBI

22 

Benekli M, Baer MR, Baumann H and Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood. 101:2940–2954. 2003. View Article : Google Scholar

23 

Coffer PJ, Koenderman L and de Groot RP: The role of STATs in myeloid differentiation and leukemia. Oncogene. 19:2511–2522. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Chakraborty A and Tweardy DJ: Granulocyte colony-stimulating factor activates a 72-kDa isoform of STAT3 in human neutrophils. J Leukoc Biol. 64:675–680. 1998. View Article : Google Scholar : PubMed/NCBI

25 

Hevehan DL, Miller WM and Papoutsakis ET: Differential expression and phosphorylation of distinct STAT3 proteins during granulocytic differentiation. Blood. 99:1627–1637. 2002. View Article : Google Scholar : PubMed/NCBI

26 

Pilati C and Zucman-Rossi J: Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev. 26:499–506. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar

28 

Groner B, Lucks P and Borghouts C: The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol. 19:341–350. 2008. View Article : Google Scholar : PubMed/NCBI

29 

Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T and Akira S: Correction: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol. 194:35262015. View Article : Google Scholar : PubMed/NCBI

30 

Levy DE and Lee CK: What does Stat3 do? J Clin Invest. 109:1143–1148. 2002. View Article : Google Scholar : PubMed/NCBI

31 

Bournazou E and Bromberg J: Targeting the tumor microenvironment: JAK-STAT3 signaling. JAK-STAT. 2:e238282013. View Article : Google Scholar : PubMed/NCBI

32 

Guo H, Zhou H, Lu J, Qu Y, Yu D and Tong Y: Vascular endothelial growth factor: An attractive target in the treatment of hypoxic/ischemic brain injury. Neural Regen Res. 11:174–179. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Leonard WJ and O'Shea JJ: Jaks and STATs: Biological implications. Annu Rev Immunol. 16:293–322. 1998. View Article : Google Scholar : PubMed/NCBI

34 

Schindler C and Strehlow I: Cytokines and STAT signaling. Adv Pharmacol. 47:113–174. 2000. View Article : Google Scholar

35 

Kisseleva T, Bhattacharya S, Braunstein J and Schindler CW: Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 285:1–24. 2002. View Article : Google Scholar : PubMed/NCBI

36 

Kang SK, Kang KS, Jee MK and Kim BS: Vascular endothelial growth factor/kinase insult domain receptor (KDR)/fetal liver kinase 1 (FLK1)-mediated skin-epithelial progenitor cells reprogramming. Tissue Eng Part A. 16:2687–2697. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Pastuschek J, Poetzsch J, Morales-Prieto DM, Schleussner E, Markert UR and Georgiev G: Stimulation of the JAK/STAT pathway by LIF and OSM in the human granulosa cell line COV434. J Reprod Immunol. 108:48–55. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Marino VJ and Roguin LP: The granulocyte colony stimulating factor (G-CSF) activates Jak/STAT and MAPK pathways in a trophoblastic cell line. J Cell Biochem. 103:1512–1523. 2008. View Article : Google Scholar

39 

Platanias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 5:375–386. 2005. View Article : Google Scholar : PubMed/NCBI

40 

Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S and Grandis JR: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 13:355–362. 2002.PubMed/NCBI

41 

Ram PT and Iyengar R: G protein coupled receptor signaling through the Src and Stat3 pathway: Role in proliferation and transformation. Oncogene. 20:1601–1606. 2001. View Article : Google Scholar : PubMed/NCBI

42 

Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol. 165:5227–5237. 2000. View Article : Google Scholar : PubMed/NCBI

43 

Trengove MC and Ward AC: SOCS proteins in development and disease. Am J Clin Exp Immunol. 2:1–29. 2013.PubMed/NCBI

44 

Piessevaux J, Lavens D, Peelman F and Tavernier J: The many faces of the SOCS box. Cytokine Growth Factor Rev. 19:371–381. 2008. View Article : Google Scholar : PubMed/NCBI

45 

Shuai K: Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 16:196–202. 2006. View Article : Google Scholar : PubMed/NCBI

46 

Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J and Xia L: Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. Leuk Lymphoma. 51:1326–1336. 2010. View Article : Google Scholar : PubMed/NCBI

47 

Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF and Tweardy DJ: Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood. 88:2442–2449. 1996.PubMed/NCBI

48 

Quotti Tubi L, Canovas Nunes S, Brancalion A, Doriguzzi Breatta E, Manni S, Mandato E, Zaffino F, Macaccaro P, Carrino M, Gianesin K, et al: Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. Leukemia. 31:292–300. 2017. View Article : Google Scholar

49 

Mencalha AL, Binato R, Ferreira GM, Du Rocher B and Abdelhay E: Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One. 7:e481602012. View Article : Google Scholar : PubMed/NCBI

50 

Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA and Zhao JJ: NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2:160302016. View Article : Google Scholar : PubMed/NCBI

51 

Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, Forman S, Perrotti D, Jove R and Bhatia R: Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood. 123:2826–2837. 2014. View Article : Google Scholar : PubMed/NCBI

52 

Sasaki R, Ito S, Asahi M and Ishida Y: YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells. Leuk Res. 39:1473–1479. 2015. View Article : Google Scholar : PubMed/NCBI

53 

Avalos BR: Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood. 88:761–777. 1996.PubMed/NCBI

54 

Hillmer EJ, Zhang H, Li HS and Watowich SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev. 31:1–15. 2016. View Article : Google Scholar : PubMed/NCBI

55 

Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, El Kasmi KC, Liu F, Goldsmith MA, Link DC, Murray PJ, et al: STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood. 108:3682–3690. 2006. View Article : Google Scholar : PubMed/NCBI

56 

Krönke M, Schlüter C and Pfizenmaier K: Tumor necrosis factor inhibits MYC expression in HL-60 cells at the level of mRNA transcription. Proc Natl Acad Sci USA. 84:469–473. 1987. View Article : Google Scholar : PubMed/NCBI

57 

Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR and Tenen DG: c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 21:3789–3806. 2001. View Article : Google Scholar : PubMed/NCBI

58 

Xu S, Xu Z, Liu B, Sun Q, Yang L, Wang J, Wang Y and Liu H: LIFRα-CT3 induces differentiation of a human acute myelogenous leukemia cell line HL-60 by suppressing miR-155 expression through the JAK/STAT pathway. Leuk Res. 38:1237–1244. 2014. View Article : Google Scholar : PubMed/NCBI

59 

Uchino Y, Iriyama N, Hatta Y and Takei M: Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A. Cancer Cell Int. 15:302015. View Article : Google Scholar : PubMed/NCBI

60 

Xu N, Tang XH, Pan W, Xie ZM, Zhang GF, Ji MH, Yang JJ, Zhou MT and Zhou ZQ: Spared nerve injury increases the expression of microglia M1 markers in the prefrontal cortex of rats and provokes depression-like behaviors. Front Neurosci. 11:2092017. View Article : Google Scholar :

61 

Allman WR, Dey R, Liu L, Siddiqui S, Coleman AS, Bhattacharya P, Yano M, Uslu K, Takeda K, Nakhasi HL, et al: TACI deficiency leads to alternatively activated macrophage phenotype and susceptibility to Leishmania infection. Proc Natl Acad Sci USA. 112:E4094–E4103. 2015. View Article : Google Scholar : PubMed/NCBI

62 

Zhou L, Zhuo H, Ouyang H, Liu Y, Yuan F, Sun L, Liu F and Liu H: Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. Cell Immunol. 316:53–60. 2017. View Article : Google Scholar : PubMed/NCBI

63 

Binnemars-Postma K, Storm G and Prakash J: Nanomedicine strategies to target tumor-associated macrophages. Int J Mol Sci. 18:9792017. View Article : Google Scholar :

64 

Fu XL, Duan W, Su CY, Shen XQ, Zhuang Y, Yu PW and Zhao YL: IL-6 cooperated with M-CSF induce CD14+ monocytes differentiation into M2-like phenotype macrophages in vitro. Immunol J. 32:1013–1018. 2016.In Chinese.

65 

Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, et al: M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 51:93–99. 2011. View Article : Google Scholar : PubMed/NCBI

66 

Mangan JK, Rane SG, Kang AD, Amanullah A, Wong BC and Reddy EP: Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood. 103:4093–4101. 2004. View Article : Google Scholar : PubMed/NCBI

67 

Iwamoto T, Senga T, Adachi K and Hamaguchi M: Stat3-dependent induction of interleukin-3 receptor expression in leukemia inhibitory factor-stimulated M1 mouse leukemia cells. Cytokine. 25:136–139. 2004. View Article : Google Scholar

68 

Tanuma N, Nakamura K, Shima H and Kikuchi K: Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. J Biol Chem. 275:28216–28221. 2000.PubMed/NCBI

69 

Yao Y, Zhou Q and Ericson SG: Vanadate stimulates monocytic differentiation activity of IL-6 by enhancing actin filament polymerization in HL-60 cells. J Biomed Sci. 11:940–949. 2004. View Article : Google Scholar : PubMed/NCBI

70 

Woetmann A, Nielsen M, Christensen ST, Brockdorff J, Kaltoft K, Engel AM, Skov S, Brender C, Geisler C, Svejgaard A, et al: Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3. Proc Natl Acad Sci USA. 96:10620–10625. 1999. View Article : Google Scholar : PubMed/NCBI

71 

Sun Q, Wang J, Xiong J, Yang L and Liu H: Free LIF receptor α-chain distal cytoplasmic motifs enhance Jak2-independent STAT3 phosphorylation and induce differentiation in HL-60 cells. Oncol Rep. 26:399–404. 2011.PubMed/NCBI

72 

Zhou J, Chong PS, Lu X, Cheong LL, Bi C, Liu SC, Zhou Y, Tan TZ, Yang H, Chung TH, et al: Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. Exp Hematol. 42:1041–1052. e1–2. 2014. View Article : Google Scholar : PubMed/NCBI

73 

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol. 18:767–811. 2000. View Article : Google Scholar : PubMed/NCBI

74 

Liu YJ, Kanzler H, Soumelis V and Gilliet M: Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2:585–589. 2001. View Article : Google Scholar : PubMed/NCBI

75 

Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Brière F, de Lamballeri XN, Isnardon D, Sainty D, Olive D and Gaugler B: Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood. 98:3750–3756. 2001. View Article : Google Scholar : PubMed/NCBI

76 

Claxton DF, McMannis J, Champlin R and Choudhury A: Therapeutic potential of leukemia-derived dendritic cells: Preclinical and clinical progress. Crit Rev Immunol. 21:147–155. 2001. View Article : Google Scholar : PubMed/NCBI

77 

Wu L and Liu YJ: Development of dendritic-cell lineages. Immunity. 26:741–750. 2007. View Article : Google Scholar : PubMed/NCBI

78 

McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, et al: Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 95:3489–3497. 2000.PubMed/NCBI

79 

Waskow C, Liu K, Darrasse-Jèze G, Guermonprez P, Ginhoux F, Merad M, Shengelia T, Yao K and Nussenzweig M: The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 9:676–683. 2008. View Article : Google Scholar : PubMed/NCBI

80 

Li HS, Yang CY, Nallaparaju KC, Zhang H, Liu YJ, Goldrath AW and Watowich SS: The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development. Blood. 120:4363–4373. 2012. View Article : Google Scholar : PubMed/NCBI

81 

Brady MT, Miller A, Sait SN, Ford LA, Minderman H, Wang ES, Lee KP, Baumann H and Wetzler M: Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leuk Res. 37:822–828. 2013. View Article : Google Scholar : PubMed/NCBI

82 

Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, et al: Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 113:4052–4062. 2009. View Article : Google Scholar : PubMed/NCBI

83 

Nair RR, Tolentino JH and Hazlehurst LA: Role of STAT3 in transformation and drug resistance in CML. Front Oncol. 2:302012. View Article : Google Scholar : PubMed/NCBI

84 

Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, et al: STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 12:1267–1282. 2014. View Article : Google Scholar : PubMed/NCBI

85 

Mencalha AL, Du Rocher B, Salles D, Binato R and Abdelhay E: LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother Pharmacol. 65:1039–1046. 2010. View Article : Google Scholar

86 

Mangolini M, de Boer J, Walf-Vorderwülbecke V, Pieters R, den Boer ML and Williams O: STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. Blood. 122:542–549. 2013. View Article : Google Scholar

87 

Pathania AS, Kumar S, Guru SK, Bhushan S, Sharma PR, Aithagani SK, Singh PP, Vishwakarma RA, Kumar A and Malik F: The synthetic tryptanthrin analogue suppresses STAT3 signaling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60 cells. PLoS One. 9:e1104112014. View Article : Google Scholar : PubMed/NCBI

88 

Pathania AS, Guru SK, Ul Ashraf N, Riyaz-Ul-Hassan S, Ali A, Abdullah Tasduq S, Malik F and Bhushan S: A novel stereo bioactive metabolite isolated from an endophytic fungus induces caspase dependent apoptosis and STAT-3 inhibition in human leukemia cells. Eur J Pharmacol. 765:75–85. 2015. View Article : Google Scholar : PubMed/NCBI

89 

Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, et al: At high levels, constitutively activated STAT3 induces apoptosis of chronic lymphocytic leukemia cells. J Immunol. 196:4400–4409. 2016. View Article : Google Scholar : PubMed/NCBI

90 

Xia Z, Sait SN, Baer MR, Barcos M, Donohue KA, Lawrence D, Ford LA, Block AM, Baumann H and Wetzler M: Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. Leuk Res. 25:473–482. 2001. View Article : Google Scholar : PubMed/NCBI

91 

Stevens AM, Ruiz MJ, Gerbing RB, Alonzo TA, Gamis AS and Redell MS: Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Haematologica. 100:e496–e500. 2015. View Article : Google Scholar : PubMed/NCBI

92 

Benekli M1, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H and Wetzler M: Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002:252–257. 2002. View Article : Google Scholar

93 

Kristensen T, Larsen M, Rewes A, Frederiksen H, Thomassen M and Møller MB: Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in T-cell large granular lymphocytic leukemia. J Mol Diagn. 16:382–392. 2014. View Article : Google Scholar : PubMed/NCBI

94 

Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, et al: STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 120:3048–3057. 2012. View Article : Google Scholar : PubMed/NCBI

95 

Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, et al: The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica. 100:91–99. 2015. View Article : Google Scholar :

96 

Lamy T and Loughran TP Jr: How I treat LGL leukemia. Blood. 117:2764–2774. 2011. View Article : Google Scholar :

97 

Lamy T, Moignet A and Loughran TP Jr: LGL leukemia: From pathogenesis to treatment. Blood. 129:1082–1094. 2017. View Article : Google Scholar : PubMed/NCBI

98 

Matutes E: Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert Rev Hematol. 10:251–258. 2017. View Article : Google Scholar : PubMed/NCBI

99 

Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL and Arber DA: STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia. 27:2244–2247. 2013. View Article : Google Scholar : PubMed/NCBI

100 

Zhong Y, Wu J, Chen B, Ma R, Cao H, Wang Z, Cheng L, Ding J and Feng J: Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia. Leuk Lymphoma. 53:1216–1221. 2012. View Article : Google Scholar

101 

Lautner-Csorba O, Gézsi A, Semsei AF, Antal P, Erdélyi DJ, Schermann G, Kutszegi N, Csordás K, Hegyi M, Kovács G, et al: Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance. BMC Med Genomics. 5:422012. View Article : Google Scholar : PubMed/NCBI

102 

Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, Platanias L and Eklund EA: Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab. 114:397–402. 2015. View Article : Google Scholar :

103 

Bruserud Ø, Nepstad I, Hauge M, Hatfield KJ and Reikvam H: STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia. Expert Rev Hematol. 8:29–41. 2015. View Article : Google Scholar

104 

Munoz J, Dhillon N, Janku F, Watowich SS and Hong DS: STAT3 inhibitors: Finding a home in lymphoma and leukemia. Oncologist. 19:536–544. 2014. View Article : Google Scholar : PubMed/NCBI

105 

Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Kurahashi S and Naoe T: A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 3:e1662013. View Article : Google Scholar : PubMed/NCBI

106 

Zhu Z, Lu X, Jiang L, Sun X, Zhou H, Jia Z, Zhang X and Ma L: STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells. Am J Transl Res. 7:1896–1907. 2015.PubMed/NCBI

107 

Selvi N, Kaymaz BT, Gündüz C, Aktan C, Kiper HD, Sahin F, Cömert M, Selvi AF, Kosova B and Saydam G: Bortezomib induces apoptosis by interacting with JAK/STAT pathway in K562 leukemic cells. Tumour Biol. 35:7861–7870. 2014. View Article : Google Scholar : PubMed/NCBI

108 

Kiper HD, Tezcanli Kaymaz B, Gokbulut AA, Selvi N, Avci CB, Kosova B, Iskender G, Yandim MK, Gunduz C, Sahin F, et al: STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomed Pharmacother. 67:527–532. 2013. View Article : Google Scholar : PubMed/NCBI

109 

Zhao S, Guo J, Zhao Y, Fei C, Zheng Q, Li X and Chang C: Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. Am J Transl Res. 8:3169–3178. 2016.PubMed/NCBI

110 

Chan KT, Li K, Liu SL, Chu KH, Toh M and Xie WD: Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett. 289:46–52. 2010. View Article : Google Scholar

111 

Cai H, Qin X and Yang C: Dehydrocostus lactone suppresses proliferation of human chronic myeloid leukemia cells through Bcr/Abl-JAK/STAT signaling pathways. J Cell Biochem. 118:3381–3390. 2017. View Article : Google Scholar : PubMed/NCBI

112 

Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIA and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI

113 

Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M, Qian S and Jianyong L: Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort. Leuk Lymphoma. 56:2923–2930. 2015. View Article : Google Scholar : PubMed/NCBI

114 

Jia X, Yang W, Han J and Xiong H: Effects of lentivirus mediated STAT3 silencing on human chronic myeloid leukemia cells and leukemia mice. Int J Clin Exp Med. 7:4031–4037. 2014.

115 

Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L and Vigneri P: Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol Cancer Ther. 12:1085–1098. 2013. View Article : Google Scholar : PubMed/NCBI

116 

Allen JC, Talab F, Zuzel M, Lin K and Slupsky JR: c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. Blood. 117:2414–2422. 2011. View Article : Google Scholar : PubMed/NCBI

117 

Folgiero V, Goffredo BM, Filippini P, Masetti R, Bonanno G, Caruso R, Bertaina V, Mastronuzzi A, Gaspari S, Zecca M, et al: Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget. 5:2052–2064. 2014. View Article : Google Scholar : PubMed/NCBI

118 

Adamaki M, Tsotra M, Vlahopoulos S, Zampogiannis A, Papavassiliou AG and Moschovi M: STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations. Leuk Res. 39:1285–1291. 2015. View Article : Google Scholar

119 

Zhong Y, Feng J, Chen B, Cheng L, Li Y, Qian J, Ding J, Gao F and Xia G: Signal transducer and activator of transcription 3 (STAT3) gene polymorphisms are associated with treatment outcomes in acute myeloid leukemia. Int J Lab Hematol. 34:383–389. 2012. View Article : Google Scholar : PubMed/NCBI

120 

Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ and Meshinchi S; Children's Oncology Group: FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: A Children's Oncology Group report. Blood. 121:1083–1093. 2013. View Article : Google Scholar :

121 

Levidou G, Sachanas S, Pangalis GA, Kalpadakis C, Yiakoumis X, Moschogiannis M, Sepsa A, Lakiotaki E, Milionis V, Kyrtsonis MC, et al: Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: Correlation between microvascular characteristics and prognostic significance. BioMed Res Int. 2014:2514792014. View Article : Google Scholar

122 

Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, et al: Ezh2 controls an early hematopoietic program and growth and survival signaling in early T cell precursor acute lymphoblastic leukemia. Cell Rep. 14:1953–1965. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2018
Volume 53 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shi, Y., Zhang, Z., Qu, X., Zhu, X., Zhao, L., Wei, R. ... Li, X. (2018). Roles of STAT3 in leukemia (Review). International Journal of Oncology, 53, 7-20. https://doi.org/10.3892/ijo.2018.4386
MLA
Shi, Y., Zhang, Z., Qu, X., Zhu, X., Zhao, L., Wei, R., Guo, Q., Sun, L., Yin, X., Zhang, Y., Li, X."Roles of STAT3 in leukemia (Review)". International Journal of Oncology 53.1 (2018): 7-20.
Chicago
Shi, Y., Zhang, Z., Qu, X., Zhu, X., Zhao, L., Wei, R., Guo, Q., Sun, L., Yin, X., Zhang, Y., Li, X."Roles of STAT3 in leukemia (Review)". International Journal of Oncology 53, no. 1 (2018): 7-20. https://doi.org/10.3892/ijo.2018.4386